Marksans Pharma share price rose in the opening trade on November 6 following the company received cancer drug approval from UK MHRA.
At 09:20am, Marksans Pharma was quoting at Rs 189.10, up Rs 2.35, or 1.26 percent, on the BSE.
The company's wholly owned subsidiary Relonchem in UK has received marketing authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.
Catch all the market action on our live blog
A meeting of the board of directors of the company will be held on November 13, 2025, to consider and approve the unaudited financial results of the company (both standalone and consolidated) for the quarter and half year ended September 30, 2025.
In October Relonchem received marketing authorization for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets, from UK MHRA.
In the previous trading session, the share closed at Rs 186.75, down Rs 3.70, or 1.94 percent.
The share touched a 52-week high of Rs 358.50 and a 52-week low of Rs 162.05 on 05 December, 2024 and 07 October, 2025, respectively.
Currently, the stock is trading 47.25 percent below its 52-week high and 16.69 percent above its 52-week low.
The market capitalisation of the company stands at Rs 8,569.33 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
